Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

This study has been completed.
Celgene Corporation
Information provided by (Responsible Party):
Elizabeth Camacho, New York University School of Medicine Identifier:
First received: July 1, 2008
Last updated: December 10, 2012
Last verified: December 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2010
  Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)